| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036736565 |
| P356 | DOI | 10.1038/339303A0 |
| P698 | PubMed publication ID | 2524666 |
| P2093 | author name string | Nachman RL | |
| Hajjar KA | |||
| Breslow JL | |||
| Gavish D | |||
| P2860 | cites work | cDNA sequence of human apolipoprotein(a) is homologous to plasminogen | Q28302632 |
| LIGAND: A versatile computerized approach for characterization of ligand-binding systems | Q29547346 | ||
| Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen | Q34622938 | ||
| Binding of tissue plasminogen activator to cultured human endothelial cells | Q35583510 | ||
| Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface | Q35593586 | ||
| Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators | Q36206428 | ||
| Lipoprotein(a): a genetically determined lipoprotein containing a glycoprotein of the plasminogen family | Q39487966 | ||
| Sinking pre-beta lipoprotein and coronary heart disease in Japanese-American men in Hawaii | Q40194504 | ||
| Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site | Q41270276 | ||
| Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma | Q41357121 | ||
| Linkage between the loci for the Lp(a) lipoprotein (LP) and plasminogen (PLG). | Q42035069 | ||
| Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients | Q43788568 | ||
| The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels | Q70021110 | ||
| Binding of tissue plasminogen activator to human umbilical vein endothelial cells | Q70346718 | ||
| Protein composition of Lp(a) lipoprotein from human plasma | Q72779344 | ||
| P433 | issue | 6222 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| atherosclerosis | Q12252367 | ||
| LPA | Q18028636 | ||
| P304 | page(s) | 303-305 | |
| P577 | publication date | 1989-05-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis | |
| P478 | volume | 339 |
| Q40926437 | A pivotal role for TGF-beta in atherogenesis? |
| Q52425625 | A structural assessment of the apo[a] protein of human lipoprotein[a] |
| Q86645830 | An Increased Serum Level of Lipoprotein(a) Is a Predictor for Deep Vein Thrombosis in Patients with Spinal Cord Injuries |
| Q48355917 | Analysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy. |
| Q41500703 | Annexin II: a novel mediator of cell surface plasmin generation |
| Q41671750 | Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis |
| Q33612119 | Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease |
| Q35796463 | Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. |
| Q41071697 | Apolipoproteins: pathophysiology and clinical implications |
| Q40430415 | Arterial thrombosis for the clinician. Pathobiology and emerging concepts. |
| Q33601790 | Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux |
| Q46953909 | Atherogenesis in transgenic mice expressing human apolipoprotein(a) |
| Q30489063 | Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies |
| Q33544622 | Biochemical risk factors and patient's outcome: the case of lipoprotein(a). |
| Q44235869 | Blood Rheology and Cardiovascular Risk Factors in Type 1 Diabetes: Relationship with Microalbuminuria |
| Q51570754 | Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore. |
| Q36422578 | Cellular processes in atherogenesis: Potential targets of Ca2+ channel blockers |
| Q33704490 | Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore |
| Q67593700 | Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin |
| Q42860196 | Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates |
| Q33777699 | Cholesterol lowering and endothelial function |
| Q41500665 | Clinical trials to prevent restenosis after percutaneous coronary revascularization |
| Q40841563 | Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects |
| Q79086224 | Does Lipoprotein(a) Inhibit Elastolysis in Abdominal Aortic Aneurysms? |
| Q35127904 | Does lipoprotein (a) level have a predictive value in restenosis after coronary stenting? |
| Q33789283 | Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity |
| Q34663551 | Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia |
| Q37401506 | Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. |
| Q73169690 | Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site |
| Q39439221 | Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? |
| Q47808589 | Elevated plasma levels of soluble P-selectin in patients with acute myocardial infarction and unstable angina. An inverse link to lipoprotein(a). |
| Q44080311 | Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma |
| Q44175752 | Elevated serum lipoprotein(a) in subclinical hypothyroidism |
| Q77643955 | Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study |
| Q37332176 | Endothelial cell fibrinolytic assembly |
| Q35093076 | Endothelium and the lipid metabolism: the current understanding. |
| Q42499863 | Endothelium-dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a). |
| Q41666481 | Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element |
| Q38701405 | Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis |
| Q35197067 | Expressed hypervariable polymorphism of apolipoprotein (a). |
| Q35094413 | Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice |
| Q71858695 | Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques |
| Q73102117 | Factors contributing to variation in lipoprotein (a) in Melbourne Anglo-Celtic population |
| Q77198446 | Familial dysplasminogenemia with central retinal vein and cilioretinal artery occlusion |
| Q35224510 | Fibrin, Lipoprotein(a), Plasmin Interactions: A Model Linking Thrombosis and Atherogenesisa |
| Q37379082 | Fibrinogen deficiency is compatible with the development of atherosclerosis in mice |
| Q36527433 | Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice |
| Q40406437 | Fibrinolysis and atherosclerosis |
| Q73901485 | Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators |
| Q43504139 | Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells |
| Q34297896 | High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes |
| Q71244214 | High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease |
| Q46395475 | Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm |
| Q36725776 | Highly repeated sites in the apolipoprotein(a) gene recognized by methylated DNA-binding protein, a sequence-specific DNA-binding protein |
| Q37271062 | Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism |
| Q35612116 | Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor |
| Q41141603 | Hormone replacement therapy and hemostasis: principles of a complex interaction |
| Q34107469 | Hormone replacement therapy in the prevention and treatment of atherosclerosis |
| Q36686804 | Hormone therapy and cardiovascular disease |
| Q42554735 | Human Low Density Lipoprotein (LDL) and Human Serum Albumin (HSA) Co-Adsorption Onto the C18-Silica Gradient Surface |
| Q71220053 | Hyperglycemia-induced latent scurvy and atherosclerosis: the scorbutic-metaplasia hypothesis |
| Q51573704 | Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. |
| Q24557502 | Hypothesis: lipoprotein(a) is a surrogate for ascorbate |
| Q36381031 | Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva |
| Q38297505 | Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). |
| Q72113121 | Influence of apolipoprotein(a) phenotype on lipoprotein(a) quantification: Evaluation of three methods |
| Q71827307 | Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine |
| Q53655587 | Inhibition of Angiogenesis and Angiogenesis-dependent Tumor Growth by the Cryptic Kringle Fragments of Human Apolipoprotein(a) |
| Q38528622 | Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). |
| Q40512049 | Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages |
| Q47328645 | Interrelationship of triglyceride-rich lipoproteins, serum lipoprotein (a) concentration and apolipoprotein(a) size |
| Q74314734 | Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study |
| Q42861747 | Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation |
| Q37088275 | LP(a) as a marker for coronary heart disease risk |
| Q41024567 | Laboratory diagnosis of hemorrhagic and thrombotic disorders. |
| Q74233396 | Lack of association of serum lipoprotein (a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease |
| Q33944588 | Lipoprotein (a) and the risk of ischemic stroke in young women |
| Q41167018 | Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis |
| Q39610949 | Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia |
| Q44043195 | Lipoprotein (a) blood levels in unstable angina pectoris, acute myocardial infarction, and after thrombolytic therapy |
| Q58421413 | Lipoprotein (a) does not influence hyperfibrinolysis in patients with liver cirrhosis |
| Q36529887 | Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration |
| Q46861418 | Lipoprotein (a) is a substrate for factor XIIIa and tissue transglutaminase |
| Q71564202 | Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions |
| Q73406829 | Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia |
| Q42800361 | Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin |
| Q41695853 | Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis |
| Q50949167 | Lipoprotein (a) serum levels in patients with hepatocarcinoma. |
| Q37853403 | Lipoprotein (a). Heterogeneity and biological relevance |
| Q34020677 | Lipoprotein (a): structure, pathophysiology and clinical implications. |
| Q36843336 | Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? |
| Q34078108 | Lipoprotein Lp(a) and atherothrombotic disease. |
| Q71492130 | Lipoprotein levels in patients with pregnancy induced hypertension |
| Q40757462 | Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy |
| Q67903043 | Lipoprotein(a) |
| Q57273953 | Lipoprotein(a) Serum Levels and Vascular Diseases in an Older Caucasian Population Cohort |
| Q51606314 | Lipoprotein(a) and acute-phase proteins in acute myocardial infarction |
| Q74635708 | Lipoprotein(a) and coronary thrombosis and restenosis after stent placement |
| Q77700147 | Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation |
| Q50998785 | Lipoprotein(a) and its correlates in Japanese and U.S. population samples. |
| Q36814085 | Lipoprotein(a) and its role in occlusive vascular disease. |
| Q43654637 | Lipoprotein(a) and its role in occlusive vascular disease. |
| Q24305939 | Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it |
| Q51587807 | Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Québec Cardiovascular Study) |
| Q41197625 | Lipoprotein(a) enhances plasma clot lysis in vitro |
| Q47274864 | Lipoprotein(a) in clinical practice: New perspectives from basic and translational science |
| Q41300659 | Lipoprotein(a) in health and disease |
| Q40937490 | Lipoprotein(a) in renal disease |
| Q51593875 | Lipoprotein(a) is a risk factor for diabetic retinopathy in the elderly. |
| Q73662507 | Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm |
| Q73326758 | Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes |
| Q40444296 | Lipoprotein(a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications |
| Q73746087 | Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation |
| Q36943438 | Lipoprotein(a) serum levels in diabetic patients with retinopathy |
| Q37372596 | Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus |
| Q60176143 | Lipoprotein(a): a longitudinal versus a cross-sectional study in normal pregnancy and its levels in preeclampsia |
| Q35081894 | Lipoprotein(a): an emerging cardiovascular risk factor |
| Q35350215 | Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role |
| Q40568220 | Lipoprotein(a): new insights into an atherogenic lipoprotein |
| Q35799761 | Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. |
| Q41670628 | Lipoproteins and coagulation |
| Q40582663 | Lipoproteins and the haemostatic system in atherothrombotic disorders |
| Q70580275 | Localization of apolipoprotein(a) and B-100 in various renal diseases |
| Q46602143 | Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)? |
| Q43905985 | Low-density lipoprotein apheresis: clinical results with different methods |
| Q71622296 | Low-density lipoprotein-apheresis in two patients with extremely elevated lipoprotein (a) levels |
| Q48349049 | Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke |
| Q33578322 | Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease |
| Q44604661 | Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen |
| Q28138192 | Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains |
| Q67852238 | Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans |
| Q37370315 | Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice |
| Q42435584 | Modulation of the expression of tissue plasminogen activator and its inhibitor by hypoxia in human peritoneal and adhesion fibroblasts |
| Q58297863 | Molecular Basis of Hyperlipidemias: Lessons from the Finnish Gene Inheritage |
| Q50423780 | Molecular Regulation of Sprouting Angiogenesis |
| Q34412757 | Molecular mechanisms of fibrinolysis. |
| Q58294696 | Monitoring the oxidative modification of lipoprotein(a) by capillary zone electrophoresis |
| Q64954189 | N-acetylcysteine and serum concentrations of lipoprotein(a) |
| Q28218040 | Novel serologic markers of cardiovascular risk |
| Q37774235 | Obesity-related non-communicable diseases: South Asians vs White Caucasians |
| Q40877161 | Oestrogens and atherosclerotic vascular disease--lipid factors |
| Q73112072 | Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells |
| Q41564035 | Pathophysiological implication of the structural domains of lipoprotein(a). |
| Q73245485 | Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels |
| Q57193293 | Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease |
| Q33664574 | Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? |
| Q41100535 | Plasminogen activation on tumor cell surface and its involvement in human leukemia. |
| Q40458696 | Postmenopausal Hormone-Replacement Therapy and Cardiovascular Risk |
| Q33683302 | Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection |
| Q33608889 | Prevalence of microalbuminuria, lipoprotein (a) and coronary artery disease in the lipid clinic |
| Q35651981 | Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Apolipoprotein B, lipoprotein[a], and transplantation arteriopathy |
| Q52220887 | Reflex testing I: algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment. |
| Q53540576 | Relationship between lipoprotein(a) and spontaneous recanalization of infarct-related arteries in the early phase of acute myocardial infarction. |
| Q74182587 | Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients |
| Q73551754 | Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction |
| Q43813333 | Relationship of early carotid artery disease with lipoprotein (a), apolipoprotein B, and fibrinogen in asymptomatic essential hypertensive patients and normotensive subjects. |
| Q32056571 | Relationship of lipoprotein(a) to variables of coagulation in hypertensive subjects |
| Q40220430 | Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction |
| Q71606947 | Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women |
| Q35541858 | Role of Monocytes in Atherogenesis |
| Q36812940 | Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction |
| Q36824175 | Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction |
| Q80853466 | Serum lipoprotein(a) levels in patients with atherosclerotic peripheral vascular disease in Hospital Kuala Lumpur |
| Q36997673 | Sex hormones, lipoproteins, and cardiovascular risk |
| Q37780797 | Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems |
| Q71625829 | Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis |
| Q28211363 | Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance |
| Q37201891 | The ApoB 100-Apo(a) Complex: Relation to Triglyceride-Rich Particles |
| Q35028300 | The annexin A2 system and vascular homeostasis |
| Q44683576 | The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells |
| Q37374146 | The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor |
| Q71833673 | The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a) |
| Q39448830 | The cardiovascular safety of triphasic contraceptive steroids |
| Q26853473 | The current status of lipoprotein (a) in pregnancy: a literature review |
| Q48175139 | The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke |
| Q37679552 | The endothelial cell annexin A2 system and vascular fibrinolysis |
| Q47764984 | The functional and clinical significance of the Met-->Thr substitution in Kringle IV type 10 of apolipoprotein(a). |
| Q37103972 | The plasminogen-plasmin system |
| Q48831348 | The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population |
| Q24629974 | The response-to-retention hypothesis of early atherogenesis |
| Q59054345 | Thrombogenesis linked to atherogenesis at last? |
| Q34409695 | Thrombotic vascular risk factors in inflammatory bowel disease |
| Q41041293 | Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine |
| Q72049386 | Transfer of Lipoprotein(a) and LDL Into Aortic Intima in Normal and in Cholesterol-Fed Rabbits |
| Q44109228 | Variables associated with fibrinogen in a population-based study: interaction between smoking and age on fibrinogen concentration |
| Q47447593 | Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene |
| Q36721982 | Vessel Wall-Related Risk Factors in Acute Vascular Events |
| Q35831484 | Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes |
| Q67979601 | [The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma] |
Search more.